Chinese Regulators Provide Fast-track Review Status For Lotus On Modified Version Of AstraZeneca's Bambec
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Lotus Pharmaceuticals, a Beijing-based drug maker and distributor of Western medicines, announced April 29 that the company had received clinical trial approval for its innovative anti-asthma drug R-Bambuterol Hydrochloride (laevo-bambuterol) from China's State FDA